CDT Equity Inc. (CDT) vs Virax Biolabs Group Limited (VRAX)
A side-by-side comparison of CDT Equity Inc. and Virax Biolabs Group Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CDT
CDT Equity Inc.
$0.92HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
VRAX
Virax Biolabs Group Limited
$1.92HealthcareDelayed quote: Oct 6, 2026, 3:50 PM EDT
Total return — CDT vs VRAX
growth of $100 · dividends reinvested · last 3yCDT -100.0% (-99.8%/yr)VRAX -96.8% (-68.2%/yr)VRAX compounded faster over this window
Log scale — wide-divergence pair
CDT VRAX
CDT vs VRAX: by the numbers
- •CDT is the larger company ($709070 vs $358320 market cap).
- •CDT is profitable (6.30% net margin) while VRAX runs a net loss (-40439.10%).
Metrics side by side
Valuation
| Metric | CDT | VRAX |
|---|---|---|
| P/S ratio | 0.00 | N/A |
| P/B ratio | 0.00 | 0.05 |
| EV / EBITDA | 4.13 | N/A |
Profitability
| Metric | CDT | VRAX |
|---|---|---|
| Gross margin | 0.00% | 61.90% |
| Operating margin | 0.00% | -51515.17% |
| Net margin | 6.30% | -40439.10% |
| ROE | 6.58% | -66.30% |
| ROIC | 4.47% | -83.46% |
Growth (annualized)
| Metric | CDT | VRAX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -36.87% |
Frequently asked
- Is CDT or VRAX more profitable?
- CDT runs the higher net margin — CDT at 6.30% versus VRAX at -40439.10%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.